---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-001345"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-03-01T23:59:59+00:00"
generated_at: "2026-06-27T02:47:21.250427+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech receives Nasdaq board independence deficiency notice after director death

## Summary
- Independent director Thomas C.K. Yuen passed away Feb 13, 2022, triggering noncompliance with Nasdaq Listing Rule 5605(b)(1).
- Cure period: until earlier of next annual shareholders' meeting or Feb 13, 2023; if meeting before Aug 12, 2022, compliance by Aug 12, 2022.
- Company expects to appoint a new independent director to regain compliance before the cure period expires.

## SEC filing metadata
- accession: 0001683168-22-001345
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-03-01T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/0001683168-22-001345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822001345/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-001345
- JSON: https://secwatch.observer/filing/0001683168-22-001345.json
- Plain text: https://secwatch.observer/filing/0001683168-22-001345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.